Plasma levels of risk-variant APOL1 do not associate with renal disease in a population-based cohort

Two common missense variants in APOL1 (G1 and G2) have been definitively linked to CKD in black Americans. However, not all individuals with the renal-risk genotype develop CKD, and little is known about how APOL1 variants drive disease. Given the association of APOL1 with HDL particles, which are cleared by the kidney, differences in the level or quality ofmutant APOL1-HDL particles could be causal for disease and might serve as a useful risk stratification marker.We measured plasma levels of G0 (low risk), G1, andG2 APOL1 in 3450 individuals in the DallasHeart Study using a liquid chromatography-MS method that enabled quantitation of the different variants. Additionally, we characterized native APOL1-HDL from donors with no or two APOL1 risk alleles by size-exclusion chromatography and analysis of immunopurified APOL1-HDL particles. Finally, we identified genetic loci associated with plasma APOL1 levels and tested for APOL1-dependent associationwith renal function. Althoughwe replicated the previous association between APOL1 variant status and renal function in nondiabetic individuals, levels of circulating APOL1 did not associate with microalbuminuria or GFR. Furthermore, the size or known components of APOL1-HDL did not consistently differ in subjects with the renal-risk genotype. Genetic association studies implicated variants in loci harboring haptoglobin-related protein (HPR), APOL1, and ubiquitin D (UBD) in the regulation of plasma APOL1 levels, but these variants did not associate with renal function. Collectively, these data demonstrate that the risk of renal disease associated with APOL1 is probably not related to circulating levels of the mutant protein.